Press release
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
SIGA to Appear alongside Emergent Biosolutions and Tonix Pharmaceuticals NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:
About this update from Siga Technologies Inc.
[{"type":"text","content":"SIGA to Appear alongside Emergent Biosolutions and Tonix Pharmaceuticals\nNEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its Chief Executive Officer, Phil Gomez, and Chief Scientific Officer, Dennis Hruby, will be participating in a panel on Thursday, June 23rd at 12pm ET to discuss the recent outbreaks of monkeypox in the U.K., EU, and U.S. The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals. For further information on the panel, please see below: Date & Time: Thursday, June 23rd from 12pm-1pm ETLink to join: https://us02web.zoom.us/webinar/register/WN_NQzQ-ceWTUiDpxShNw6XfA SIGA’s lead product tecovirimat (TPOXX) was approved in January 2022 by the European Medicines Agency (EMA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. SIGA has also supplied TPOXX as a compassionate use treatment for a monkeypox case in the United Kingdom, and in the U.S., where TPOXX is approved for use against smallpox, the CDC has used TPOXX to treat at least one monkeypox patient during the current outbreak. The FDA has not approved TPOXX for monkeypox in the US. ABOUT SIGA TECHNOLOGIES, INC. and TPOXX® SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) in 2022. The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vacc...